Artemis
Driving Better Clinical Trial Results through Patient-Focused Methodology

The FDA pays significant attention to the data and patient population of clinical trials, which compels pharma and biotech companies to conduct their studies in adherence to complex protocols. A diverse patient population helps gather evidence that a drug would be safe and work effectively on a broader patient pool. To that end, companies seek trusted site partners that can ensure the recruitment of diverse patient populations.

As a reliable and valuable solutions partner for CROs and pharma companies, Artemis has pivoted its business to meet the needs of its clients. For example, the firm built an entire vaccine unit within mere weeks following the pandemic and is now a premier site in California for vaccine trials. In addition, Artemis has completed various trainings to enable it to be ready for decentralized clinical trials (DCTs), with the goal of conducting a full DCT within the next three years.

Artemis was founded on the core purpose of prioritizing patients, advancing medicine, and improving the world. In addition, to its core purpose, Artemis abides by five core values that define its culture and guide key decisions about who it hires, who it promotes, and how it runs its business.

The Core Values are:
Artemis always puts patients first
Artemis deliver the best customer experience
Artemis does the right thing
Artemis works as a team
Artemis embraces continuous improvement

Further, Artemis has a team of bilingual recruiters working with ethnically diverse organizations to increase diversity in its trials. The team spreads clinical trial awareness among the public, including Hispanic, Black, and Asian communities, and ensures consistent patient recruitment while emphasizing diversity.

It supports many communities in San Diego and spreads awareness about the importance of clinical trials.

One feature that makes Artemis unique is its Phenomenal Patient Program. Every month during an internal town hall, team members submit a patient success story and are encouraged to go above and beyond their scope of work to support their patients.

“Putting patients first is a core value at Artemis,” says Mauro Ormedilla, Sr. director, operations, Artemis. “Patients choose Artemis to be their partner in research. We take that very seriously.”

As a principal investigator (PI)-centric organization, study decisions at Artemis are driven by PIs regarding protocol designs, processes, and quality improvements. These Investigators are thought leaders and leverage their vast industry expertise to offer best-in-class trial management services to clients. They use data from the clinic and healthcare landscape to make trials more inclusive and accessible. Artemis also sets internal diversity targets for trials and takes accountability for ensuring a diverse enrollment.

Following a patient-focused methodology, Artemis ensures all trial participants receive the necessary attention for their medical needs. It spends significant time training its team to properly accommodate and treat patients. In addition, Artemis partners with large CROs to pilot their training platforms and collaborates with big pharma companies to obtain funding for its diversity initiatives.

“I’m grateful to work here. We deliver reliable, verifiable, cutting-edge research services while never losing sight of our core values and culture. Happy staff, happy patients, happy clients – those are the signs of a top-tier research company,” says Ormedilla.

Being in the business for over 14 years, Artemis has worked with global clients and plans to remain hyper-focused on its core indications—vaccines, Alzheimer’s, psychiatry, and internal medicine—at both its San Diego and Riverside locations. Going further, the company plans to partner with local healthcare organizations to offer patients care beyond clinical trial programs.

“We will be seeking to provide our research patients with a seamless integration into the local healthcare community,” adds Ormedilla.